TY - JOUR
T1 - Good clinical practice recommendations for the use of PET/CT in oncology
AU - Salaün, Pierre Yves
AU - Abgral, Ronan
AU - Malard, Olivier
AU - Querellou-Lefranc, Solène
AU - Quere, Gilles
AU - Wartski, Myriam
AU - Coriat, Romain
AU - Hindie, Elif
AU - Taieb, David
AU - Tabarin, Antoine
AU - Girard, Antoine
AU - Grellier, Jean François
AU - Brenot-Rossi, Isabelle
AU - Groheux, David
AU - Rousseau, Caroline
AU - Deandreis, Désirée
AU - Alberini, Jean Louis
AU - Bodet-Milin, Caroline
AU - Itti, Emmanuel
AU - Casasnovas, Olivier
AU - Kraeber-Bodere, Françoise
AU - Moreau, Philippe
AU - Philip, Arnaud
AU - Balleyguier, Corinne
AU - Luciani, Alain
AU - Cachin, Florent
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.
AB - Positron emission tomography/computed tomography (PET/CT) is a nuclear medicine functional imaging technique with proven clinical value in oncology. PET/CT indications are continually evolving with fresh advances made through research. French practice on the use of PET in oncology was framed in recommendations based on Standards–Options–Recommendations methodology and coordinated by the French federation of Comprehensive Cancer Centres (FNLCC). The recommendations were originally issued in 2002 followed by an update in 2003, but since then, a huge number of scientific papers have been published and new tracers have been licenced for market release. The aim of this work is to bring the 2003 version recommendations up to date. For this purpose, a focus group was set up in collaboration with the French Society for Nuclear Medicine (SFMN) to work on developing good clinical practice recommendations. These good clinical practice recommendations have been awarded joint French National Heath Authority (HAS) and French Cancer Institute (INCa) label status—the stamp of methodological approval. The present document is the outcome of comprehensive literature review and rigorous appraisal by a panel of experts, organ specialists, clinical oncologists, surgeons and imaging specialists. These data were also used for the EANM referral guidelines.
KW - Computed tomography
KW - Methodological approval
KW - Positron emission tomography
UR - http://www.scopus.com/inward/record.url?scp=85074647664&partnerID=8YFLogxK
U2 - 10.1007/s00259-019-04553-8
DO - 10.1007/s00259-019-04553-8
M3 - Article
C2 - 31637482
AN - SCOPUS:85074647664
SN - 1619-7070
VL - 47
SP - 28
EP - 50
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 1
ER -